CDKN2A and chronic myelogenous leukemia, BCR-ABL1 positive: Although CDKN2A deletions support enhanced cell survival in multiple ways (such as reduced p53 activation via Mdm2 overexpression)59, the lack of negative regulation of FOXM1 may also contribute to the rapid TKI resistance development in ALL but not CML.